Pfizer’s new vaccine targets 25 pneumococcal serotypes, but can it outperform PREVNAR 20?
Pfizer's 25-valent pediatric vaccine shows strong Phase 2 immune responses, including against serotype 3. Can Phase 3 establish broader protection?
Pharma & Biotech
Pharma & Biotech
Why Vaxcyte is seeking $1bn just days after VAX-31’s pivotal vaccine readout
Vaxcyte’s VAX-31 met pivotal Phase 3 immune-response endpoints as the company prices $1 billion to fund trials and manufacturing scale-up.